Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa

  1. Liyun Zhang
  2. Conan Chen
  3. Jie Fu
  4. Brendan Lilley
  5. Cynthia Berlinicke
  6. Baranda Hansen
  7. Ding Ding
  8. Guohua Wang
  9. Tao Wang
  10. Daniel Shou
  11. Ying Ye
  12. Timothy Mulligan
  13. Kevin Emmerich
  14. Meera T Saxena
  15. Kelsi R Hall
  16. Abigail V Sharrock
  17. Carlene Brandon
  18. Hyejin Park
  19. Tae-In Kam
  20. Valina L Dawson
  21. Ted M Dawson
  22. Joong Sup Shim
  23. Justin Hanes
  24. Hongkai Ji
  25. Jun O Liu
  26. Jiang Qian
  27. David F Ackerley
  28. Baerbel Rohrer
  29. Donald J Zack
  30. Jeff S Mumm  Is a corresponding author
  1. Johns Hopkins University, United States
  2. Johns Hopkins University School of Public Health, United States
  3. Johns Hopkins University School of Medicine, United States
  4. Victoria University of Wellington, New Zealand
  5. Medical University of South Carolina, United States
  6. University of Macau, Macao

Abstract

Retinitis pigmentosa (RP) and associated inherited retinal diseases (IRDs) are caused by rod photoreceptor degeneration, necessitating therapeutics promoting rod photoreceptor survival. To address this, we tested compounds for neuroprotective effects in multiple zebrafish and mouse RP models, reasoning drugs effective across species and/or independent of disease mutation may translate better clinically. We first performed a large-scale phenotypic drug screen for compounds promoting rod cell survival in a larval zebrafish model of inducible RP. We tested 2,934 compounds, mostly human-approved drugs, across six concentrations, resulting in 113 compounds being identified as hits. Secondary tests of 42 high-priority hits confirmed eleven lead candidates. Leads were then evaluated in a series of mouse RP models in an effort to identify compounds effective across species and RP models, i.e., potential pan-disease therapeutics. Nine of eleven leads exhibited neuroprotective effects in mouse primary photoreceptor cultures, and three promoted photoreceptor survival in mouse rd1 retinal explants. Both shared and complementary mechanisms of action were implicated across leads. Shared target tests implicated parp1-dependent cell death in our zebrafish RP model. Complementation tests revealed enhanced and additive/synergistic neuroprotective effects of paired drug combinations in mouse photoreceptor cultures and zebrafish, respectively. These results highlight the value of cross-species/multi-model phenotypic drug discovery and suggest combinatorial drug therapies may provide enhanced therapeutic benefits for RP patients.

Data availability

Source data files have been uploaded

The following previously published data sets were used

Article and author information

Author details

  1. Liyun Zhang

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    Liyun Zhang, has filed a provisional patent for the discoveries described herein..
  2. Conan Chen

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  3. Jie Fu

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  4. Brendan Lilley

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  5. Cynthia Berlinicke

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  6. Baranda Hansen

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  7. Ding Ding

    Department of Biostatistics, Johns Hopkins University School of Public Health, Baltimore, United States
    Competing interests
    No competing interests declared.
  8. Guohua Wang

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  9. Tao Wang

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  10. Daniel Shou

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  11. Ying Ye

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  12. Timothy Mulligan

    Johns Hopkins University School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  13. Kevin Emmerich

    Johns Hopkins University School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  14. Meera T Saxena

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  15. Kelsi R Hall

    Victoria University of Wellington, Wellington, New Zealand
    Competing interests
    No competing interests declared.
  16. Abigail V Sharrock

    Victoria University of Wellington, Wellington, New Zealand
    Competing interests
    No competing interests declared.
  17. Carlene Brandon

    Ophthalmology, Medical University of South Carolina, Charleston, United States
    Competing interests
    No competing interests declared.
  18. Hyejin Park

    School of Biological Science, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  19. Tae-In Kam

    School of Biological Science, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  20. Valina L Dawson

    School of Biological Science, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2915-3970
  21. Ted M Dawson

    Johns Hopkins University School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6459-0893
  22. Joong Sup Shim

    Faculty of Health Sciences, University of Macau, Taipa, Macao
    Competing interests
    No competing interests declared.
  23. Justin Hanes

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
  24. Hongkai Ji

    Department of Biostatistics, Johns Hopkins University School of Public Health, Baltimore, United States
    Competing interests
    No competing interests declared.
  25. Jun O Liu

    Johns Hopkins University School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3842-9841
  26. Jiang Qian

    Johns Hopkins University School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  27. David F Ackerley

    Victoria University of Wellington, Wellington, New Zealand
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6188-9902
  28. Baerbel Rohrer

    Ophthalmology, Medical University of South Carolina, Charleston, United States
    Competing interests
    No competing interests declared.
  29. Donald J Zack

    Johns Hopkins University School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  30. Jeff S Mumm

    Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States
    For correspondence
    jmumm3@jhmi.edu
    Competing interests
    Jeff S Mumm, holds patents for the NTR inducible cell ablation system (US #7,514,595) and uses thereof (US #8,071,838 and US#8431768). Has filed a provisional patent for the discoveries described herein. All other authors have no commercial relationships..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2575-287X

Funding

Foundation Fighting Blindness (Wynn-Gund TRAP)

  • Jeff S Mumm

National Institutes of Health (P30EY001765)

  • Donald J Zack

National Institutes of Health (R01EY019320)

  • Baerbel Rohrer

Department of Veterans Affairs (RX000444 and BX003050)

  • Baerbel Rohrer

South Carolina SmartState Endowment

  • Baerbel Rohrer

Flight Attendant Medical Research Institute

  • Jun O Liu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. James J Dowling, The Hospital for Sick Children, Canada

Ethics

Animal experimentation: All animal studies described herein were performed in accordance with both the Association for Research in Vision and Ophthalmology (ARVO) statement on the "Use of Animals in Ophthalmic and Vision Research" and the National Institutes of Health (NIH) Office of Laboratory Animal Welfare (OLAW) policies regarding studies conducted in vertebrate species. Animal protocols were approved by the Animal Care and Use Committees of the Johns Hopkins University School of Medicine (protocol # FI19M489 and #MO20M253) and Medical University of South Carolina (protocol #2018-00399).

Version history

  1. Received: March 26, 2020
  2. Accepted: June 28, 2021
  3. Accepted Manuscript published: June 29, 2021 (version 1)
  4. Accepted Manuscript updated: July 9, 2021 (version 2)
  5. Version of Record published: September 8, 2021 (version 3)
  6. Version of Record updated: September 15, 2021 (version 4)

Copyright

© 2021, Zhang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,880
    views
  • 397
    downloads
  • 15
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Liyun Zhang
  2. Conan Chen
  3. Jie Fu
  4. Brendan Lilley
  5. Cynthia Berlinicke
  6. Baranda Hansen
  7. Ding Ding
  8. Guohua Wang
  9. Tao Wang
  10. Daniel Shou
  11. Ying Ye
  12. Timothy Mulligan
  13. Kevin Emmerich
  14. Meera T Saxena
  15. Kelsi R Hall
  16. Abigail V Sharrock
  17. Carlene Brandon
  18. Hyejin Park
  19. Tae-In Kam
  20. Valina L Dawson
  21. Ted M Dawson
  22. Joong Sup Shim
  23. Justin Hanes
  24. Hongkai Ji
  25. Jun O Liu
  26. Jiang Qian
  27. David F Ackerley
  28. Baerbel Rohrer
  29. Donald J Zack
  30. Jeff S Mumm
(2021)
Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa
eLife 10:e57245.
https://doi.org/10.7554/eLife.57245

Share this article

https://doi.org/10.7554/eLife.57245

Further reading

    1. Developmental Biology
    2. Neuroscience
    Amy R Poe, Lucy Zhu ... Matthew S Kayser
    Research Article

    Sleep and feeding patterns lack strong daily rhythms during early life. As diurnal animals mature, feeding is consolidated to the day and sleep to the night. In Drosophila, circadian sleep patterns are initiated with formation of a circuit connecting the central clock to arousal output neurons; emergence of circadian sleep also enables long-term memory (LTM). However, the cues that trigger the development of this clock-arousal circuit are unknown. Here, we identify a role for nutritional status in driving sleep-wake rhythm development in Drosophila larvae. We find that in the 2nd instar larval period (L2), sleep and feeding are spread across the day; these behaviors become organized into daily patterns by the 3rd instar larval stage (L3). Forcing mature (L3) animals to adopt immature (L2) feeding strategies disrupts sleep-wake rhythms and the ability to exhibit LTM. In addition, the development of the clock (DN1a)-arousal (Dh44) circuit itself is influenced by the larval nutritional environment. Finally, we demonstrate that larval arousal Dh44 neurons act through glucose metabolic genes to drive onset of daily sleep-wake rhythms. Together, our data suggest that changes to energetic demands in developing organisms trigger the formation of sleep-circadian circuits and behaviors.

    1. Cell Biology
    2. Developmental Biology
    Filip Knop, Apolena Zounarova ... Marie Macůrková
    Research Article

    During Caenorhabditis elegans development, multiple cells migrate long distances or extend processes to reach their final position and/or attain proper shape. The Wnt signalling pathway stands out as one of the major coordinators of cell migration or cell outgrowth along the anterior-posterior body axis. The outcome of Wnt signalling is fine-tuned by various mechanisms including endocytosis. In this study, we show that SEL-5, the C. elegans orthologue of mammalian AP2-associated kinase AAK1, acts together with the retromer complex as a positive regulator of EGL-20/Wnt signalling during the migration of QL neuroblast daughter cells. At the same time, SEL-5 in cooperation with the retromer complex is also required during excretory canal cell outgrowth. Importantly, SEL-5 kinase activity is not required for its role in neuronal migration or excretory cell outgrowth, and neither of these processes is dependent on DPY-23/AP2M1 phosphorylation. We further establish that the Wnt proteins CWN-1 and CWN-2 together with the Frizzled receptor CFZ-2 positively regulate excretory cell outgrowth, while LIN-44/Wnt and LIN-17/Frizzled together generate a stop signal inhibiting its extension.